September 09, 2026
London, UK
Goldman Sachs 23rd Annual Medtech and Healthcare Services Conference
September 02, 2026
virtual
SdK - Privataktionärsveranstaltung
Event for retail investors (German only)
Shaping the future of healthcare
Discover why investing in Fresenius means investing in long-term healthcare innovation. Fresenius is a relevant, system-critical healthcare company. We combine innovative medicine, advanced medical technology, and the highest quality in clinical care to shape next-level therapies.
Watch the video for a quick summary of the key reasons to invest in Fresenius.
Q2/2026 IR Market Talk episode
Watch the video for answers to key questions from the investment community!
6 reasons to invest
Across our therapy platforms, we deliver real impact for patients, professionals, and hospitals around the world. At the same time, we create long-term value for our shareholders.
Explore below a detailed overview of why Fresenius is both – a system-critical healthcare provider and a well-positioned company.
Global healthcare systems are facing critical challenges:
- Longevity gap: Aging population and rising chronic diseases
- Workforce gap: Rising shortage of medical specialists
- Efficiency gap: Increasing healthcare spend
Fresenius is part of the solution: We are actively addressing these global gaps by:
- driving affordable, innovative medicine and tailored nutrition
- advancing integrated MedTech and digital ecosystems
- strengthening our employer attractiveness!
Our unique strength lies in the strong balance between two system-critical businesses: Fresenius Kabi and Fresenius Helios:
- Fresenius Kabi supplies healthcare products for critically and chronically ill patients (Pharma, Biopharma, Nutrition & MedTech)
- Fresenius Helios is Europe’s leading private hospital operator (Helios Germany & Quirónsalud Spain)
Both businesses hold leading market positions in attractive segments and are set for strong, sustainable organic growth and margin expansion.
In October 2022, Fresenius launched its #FutureFresenius strategy. Since then, we have made significant financial and structural progress, making our company more focused, adaptive, and performance driven.
All key financial metrics in Full-Year 2024 compared to Full-Year 2022 improved – a clear sign that our strategy is working.
Visit our Fresenius Annual Report 2024 for more information.
Persistent macroeconomic volatility and emerging geopolitical tensions, Fresenius delivers consistent performance. This reflects the operating strength and continued execution of #FutureFresenius. While serving global markets, we foster a strong local presence. This way we are able to act quickly – also in uncertainties:
- With our “Local for local” approach, we are closer to our customers. This means: in Europe for Europe, in Asia for Asia, in the U.S. for the U.S.
90% of Group revenues are not exposed to U.S. tariffs, and 70% of total revenues are generated in Europe.
- The “More in America” initiative specifically strengthens our strong local presence in U.S. manufacturing.
In recent years, we have invested around 1 billion US dollars in production and logistics in the U.S. Around 70% of the medicines we sell in the U.S. are also manufactured there.
We kicked-off the next phase of #FutureFresenius – Rejuvenate – in 2025: Taking our performance to the next level!
- This means upgrading our core businesses by doing what we are doing even better! Through patient care, customer service, better processes and operations, we’re creating value day by day!
- And scaling our three therapy platforms:
- specialized (Bio)Pharma
- targeted MedTech
- holistic Care Provision
Together they offer strong potential for future growth, innovation and digitalization and thus elevating performance.
Fresenius has transformed into a more focused, performance-driven organization with a strong culture of accountability. Our mission stand firm: to save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.
With over 100 years of experience, Fresenius has grown from a small business into a global healthcare company. Through #FutureFresenius, we’ve become simpler, more adaptive, and more competitive - delivering real impact to patients, caregivers, hospitals, employees, and shareholders alike. We are ready to lead and remain an employer of choice in today’s competitive healthcare landscape.
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
With our reporting and communication formats, we provide comprehensive information on our Sustainability Framework and the management of material topics. Group-wide policies enable consistent integration of sustainability considerations in daily business operations.
In our rating overview, we present the latest scores from relevant ESG rating agencies.
Publications and Policies
In our annual sustainability reporting, we disclose required regulatory information regarding our material sustainability topics. In addition, we publish our Sustainability Highlights Magazine once a year, providing an overview of our related activities.
Sustainability Statement 2025
in accordance with the European Sustainability Reporting Standards
Our policies provide employees and business partners with clear guidance on our approach to responsible business conduct and sustainability. Among the relevant internal documents are:
Fresenius Group Code of Coduct
Rating overview
ESG rating agencies regularly evaluate and review Fresenius' sustainability performance. In doing so, they focus on different aspects across the areas of Environment, Social, and Governance (ESG).
A close dialog with our stakeholders on these topics is very important to us. We are actively working to enhance transparency on relevant topics. This is reflected in consistently good rating results.
*The use by FRESENIUS SE & CO. KGAA of any MSCI ESG RESEARCH LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of FRESENIUS SE & CO. KGAA by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or service marks of MSCI.
*Copyright ©2026 Morningstar Sustainalytics. All rights reserved. The information, data, analyses and opinions contained herein: (1) includes the proprietary information of Sustainalytics and/or its content providers; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product, project, investment strategy or consideration of any particular environmental, social or governance related issues as part of any investment strategy; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. The ESG-related information, methodologies, tool, ratings, data, and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Neither Morningstar Inc., Sustainalytics, nor their content providers accept any liability for the use of the information, for actions of third parties in respect to the information, nor are responsible for any trading decisions, damages or other losses related to the information or its use. The use of the data is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.
*Recognition page https://recognition.ecovadis.com/kJ3KvcAtU0aEFuVXXvt8tw
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. The securities described on the following pages have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States of America (the "United States") absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of such securities in the United States or anywhere else and, if offered, any such securities will be offered and sold only (i) outside of the United States in "offshore transactions" in accordance with Regulation S of the Securities Act and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements of the Securities Act.
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA, OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of or located in the United States, Canada, Australia, Japan or South Africa,
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
- Fresenius has entered into an agreement to sell approximately 7.8 million shares in Fresenius Medical Care, equivalent to approximately 2.9 per cent of Fresenius Medical Care's issued share capital
- With the transaction Fresenius continues its disciplined, value-oriented reduction of its financial investment
- Increased strategic and financial flexibility to invest in Fresenius’ growth platforms; net proceeds will be used consistently with the stated capital allocation priorities
Bad Homburg, Germany, August 20, 2026 - Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today announced taking another consistent step in its #FutureFresenius transformation by further reducing its financial investment in Fresenius Medical Care. Through the sale of 7.8 million shares worth approximately €300 million to selected institutional investors, Fresenius further strengthens its balance sheet and increases its strategic flexibility. The shares sold represent approximately 2.9 per cent of Fresenius Medical Care’s issued share capital.
“With this step, we reduce our financial investment in Fresenius Medical Care and create additional flexibility to redeploy capital into our growth platforms. That is what #FutureFresenius was built for, and it is the foundation Rejuvenate builds on - a more focused Fresenius, with a stronger balance sheet and the ability to act on the opportunities in front of us”, says Michael Sen, CEO of Fresenius.
The net proceeds will reduce Group net debt and be available for future investment.
Since the deconsolidation of Fresenius Medical Care in 2023, Fresenius has managed its holding as a financial investment. In 2025, the company sold a significant amount of its stake in Fresenius Medical Care, marking a major milestone in the #FutureFresenius transformation story. Since then Fresenius has continued to actively manage its stake through the pro rata share sale alongside Fresenius Medical Care’s share buyback programs.
The transaction announced today represents a further step in this transformation and underscores Fresenius’ commitment to disciplined capital allocation, long-term profitable growth, and sustainable value creation. Fresenius will continue to assess and manage its remaining holding over time subject to market conditions, capital allocation priorities, applicable lock-up arrangements and in line with #FutureFresenius.
Further Information
Transaction Details
- Fresenius remains subject to a lock-up on its remaining shares of up to 45 days
- The anticipated book gain in the low to mid double-digit million euro range will be reflected in Fresenius Group’s Q3 2026 results, classified as special item.
Fresenius Medical Care stake: Key Events
At the time of the deconsolidation in 2023, Fresenius held 32.2 per cent of Fresenius Medical Care’s share capital. In March 2025, Fresenius raised gross proceeds of approximately €1.1 billion through a combined offering of shares in an accelerated bookbuilding and bonds exchangeable into Fresenius Medical Care shares maturing in 2028. Fresenius retained approximately 28.6 per cent following this first sell-down. In August 2025, Fresenius Medical Care initiated a series of share buyback programs alongside which Fresenius sold shares on a pro rata basis, to approximately maintain its stake. In August 2026, Fresenius placed additional 7.8 million shares with institutional investors. Following this transaction, Fresenius holds approximately 25.0 per cent1 and remains the largest shareholder.
1 Prior to any future exchange of bonds into Fresenius Medical Care shares and prior to any share cancellation under the current Fresenius Medical Care share buyback program
About Fresenius
Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany. In the full-year 2025, Fresenius generated €22.6 billion (excluding special items) in annual revenue. Fresenius employs more than 178,000 people. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in the separately listed Fresenius Medical Care AG. With around 140 hospitals, 330 outpatient facilities and 300 occupational risk prevention centres, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 27 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.
For more information, visit fresenius.com and follow Fresenius Investor Relations on LinkedIn.
About Fresenius Medical Care
Fresenius Medical Care AG is an independent, separately listed company (XETR: FME; NYSE: FMS), in which Fresenius SE & Co. KGaA holds a financial investment of approximately 25%; Fresenius Medical Care's results are not consolidated in the Fresenius Group's revenue and earnings.
Correspondence Address
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu
Chairman of the Supervisory Board: Wolfgang Kirsch
Securities Information
Fresenius SE & Co. KGaA is listed on the Frankfurt Stock Exchange and is a member of the DAX 40 index. The shares are traded on Xetra, the electronic trading venue of Deutsche Börse, under the ticker FRE.
ISIN: DE000FRE5EN2 ● German Securities Code: FRE5EN
American Depository Receipts
Fresenius SE & Co. KGaA maintains a sponsored Level I American Depositary Receipt programme, traded over the counter in the United States on the OTC Markets platform under the ticker FSNUY, at a ratio of four American Depositary Receipts to one ordinary share. Depositary bank: J.P. Morgan Chase Bank N.A.
ISIN: US35804M1053 ● CUSIP: 35804M105
Contacts
For Media contacts, click here, and to contact Investor Relations, click here.
Forward-Looking Statements
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
IMPORTANT NOTICE
This announcement is not a prospectus and does not contain or constitute an offer of securities for sale in or into any jurisdiction, including the United States, Canada, Australia, Japan, South Africa or any jurisdiction in which offers or sales of the securities would be prohibited by applicable law. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction.
This announcement is not an offer to sell, or solicitation of an offer to buy, any securities in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of the securities described herein in the United States or anywhere else.
In member states of the European Economic Area ("EEA") and the United Kingdom, this announcement is directed exclusively at persons who are "qualified investors" within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 ("Prospectus Regulation") or the Public Offers and Admissions to Trading Regulations 2024 ("POATRs") ("Qualified Investors").
In addition, in the UK, this announcement is only being distributed to and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities falling within Article 49(2) of the Order, and (iii) persons at or to whom it can otherwise lawfully be distributed or directed (all such persons together being referred to as "relevant persons"). Any person who is not a relevant person should not act or rely on this announcement or any of its contents.
The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.
This announcement may include statements that are, or may be deemed to be, "forward‐looking statements". These forward‐looking statements may be identified by the use of forward‐looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward‐looking statements may and often do differ materially from actual results. Any forward‐looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to its business, results of operations, financial position, liquidity, prospects, growth or strategies. Forward‐looking statements speak only as of the date they are made.
The Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.
No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change.